The Prognostic Value of Programmed Cell Death Protein Ligand 1 in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacille Calmette-Guérin Immunotherapy: Current Status

Overview

Journal Arab J Urol

Date 2021 Mar 25

PMID 33763250

Citations 4

Authors

Lukasz Nowak

Wojciech Krajewski

Adrian Poterek

Anna Sliwa

Romuald Zdrojowy

Affiliations

Soon will be listed here.

Abstract

Objective: To summarise the current evidence of the significance and prognostic value of programmed cell death protein ligand 1 (PD-L1) expression in patients with non-muscle-invasive bladder cancer (NMIBC) treated with bacille Calmette-Guérin (BCG) immunotherapy.

Methods: A search was conducted in May 2020 of three electronic databases; MEDLINE, Scopus, and EMBASE. In this review we included results from original studies investigating the relationship between the PD-L1 expression and BCG response in patients with NMIBC.

Results: Only five relevant articles were identified in the literature to date. Some studies showed an association between increased PD-L1 expression and BCG unresponsiveness; however, other authors provided contradictory results and suggested that PD-L1 evaluation could not be used for reliable prediction of BCG response.

Conclusions: The value of PD-L1 evaluation in predicting BCG response is debatable. Current evidence, based only on retrospective analyses, is inconsistent. Comparability of the results is diminished by the methodological limitations of immunohistochemistry assessment. Further multicentre, randomised trials are needed to make definitive conclusions.

Abbreviations: ICs: immune cells; IHC: immunohistochemical staining; (N)MIBC: (non-) muscle-invasive bladder cancer; PD-L1: programmed cell death protein ligand 1; PD-1: programmed cell death protein 1; RC: radical cystectomy; TCs: tumour cells.

Citing Articles

PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG.

de Jong F, Kvikstad V, Hoedemaeker R, van der Made A, van der Bosch T, van Casteren N World J Urol. 2025; 43(1):57.

PMID: 39752014 PMC: 11698758. DOI: 10.1007/s00345-024-05392-5.

Transurethral resection of bladder tumor with Bacille Calmette-Guerin intravesical instillation for HRNMIBC and factors influencing recurrence.

Xu A, Liu M, Han C, Wang Z, Jia B, Zhao S Am J Transl Res. 2024; 16(11):6914-6924.

PMID: 39678572 PMC: 11645617. DOI: 10.62347/UVFF9164.

Integrating the PD-L1 Prognostic Biomarker in Non-Muscle Invasive Bladder Cancer in Clinical Practice-A Comprehensive Review on State-of-the-Art Advances and Critical Issues.

Sanguedolce F, Falagario U, Zanelli M, Palicelli A, Zizzo M, Busetto G J Clin Med. 2024; 13(8).

PMID: 38673455 PMC: 11050441. DOI: 10.3390/jcm13082182.

Human epidermal growth factor receptor 2 (HER2) and the future of bladder carcinoma.

Sarkis J, Alkassis M, Assaf J Arab J Urol. 2021; 18(4):273-274.

PMID: 33425393 PMC: 7755410. DOI: 10.1080/2090598X.2020.1835439.

References

Babjuk M, Burger M, Comperat E, Gontero P, Mostafid A, Palou J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019; 76(5):639-657. DOI: 10.1016/j.eururo.2019.08.016. View

Breyer J, Wirtz R, Otto W, Erben P, Worst T, Stoehr R . High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. Cancer Immunol Immunother. 2017; 67(3):403-412. PMC: 11028240. DOI: 10.1007/s00262-017-2093-9. View

Wang X, Teng F, Kong L, Yu J . PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016; 9:5023-39. PMC: 4990391. DOI: 10.2147/OTT.S105862. View

Hussain S, Birtle A, Crabb S, Huddart R, Small D, Summerhayes M . From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. Eur Urol Oncol. 2019; 1(6):486-500. DOI: 10.1016/j.euo.2018.05.011. View

Kates M, Matoso A, Choi W, Baras A, Daniels M, Lombardo K . Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clin Cancer Res. 2019; 26(4):882-891. DOI: 10.1158/1078-0432.CCR-19-1920. View

Pierconti F, Raspollini M, Martini M, Larocca L, Bassi P, Bientinesi R . PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders. Virchows Arch. 2020; 477(2):269-277. DOI: 10.1007/s00428-020-02755-2. View

Aydin A, Baydar D, Hazir B, Babaoglu B, Bilen C . Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy. World J Urol. 2020; 38(10):2537-2545. DOI: 10.1007/s00345-019-03065-2. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2011; 3(3):e123-30. PMC: 3090117. View

Powles T, Walker J, Williams J, Bellmunt J . The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. Cancer Treat Rev. 2019; 82:101925. DOI: 10.1016/j.ctrv.2019.101925. View

10.

Delcourt C, Gemival P, Nouhaud F, Gobet F, Gillibert A, Ferlicot S . Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC). World J Urol. 2019; 38(6):1517-1524. DOI: 10.1007/s00345-019-02896-3. View

11.

Martinez R, Tapia G, De Muga S, Hernandez A, Gonzalez Cao M, Teixido C . Combined assessment of peritumoral Th1/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC. Oncoimmunology. 2019; 8(8):1602460. PMC: 6682363. DOI: 10.1080/2162402X.2019.1602460. View

12.

Slusarczyk A, Zapala P, Zapala L, Piecha T, Radziszewski P . Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics. Int Urol Nephrol. 2019; 51(7):1089-1099. DOI: 10.1007/s11255-019-02183-5. View